About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The research group is focused on finding new molecular therapeutic targets and biomarkers based on knowledge of the biology of paediatric tumours, leukemias and hematologic diseases. The experience of the group in recent years has permitted the identification of new molecular targets that are very close to the clinical phase. In this stage, we have consolidated collaborations with the biotechnological industry in order to develop small molecules able to inhibit pro-oncogenic processes such as invasion or proliferation, with the aim of providing patients with innovative and more specific biological evidence-based therapies.
Another line of research is based on the study of liquid biopsy to develop a system based on NGS to monitor the probability of relapses.
Furthermore, we have implemented a personalized medicine program to guide the management of patients based on the molecular alterations of their tumours
IP: Miguel Segura Ginard Collaborators: Maria Jose Pérez García, Lorena Valero Arrese, Adria Molero Valenzuela, Khloud Abdo Soliman Elsharawy Funding agency: Instituto de Salud Carlos III Funding: 315000 Reference: PI23/01144 Duration: 01/01/2024 - 31/12/2026
IP: Miguel Segura Ginard Collaborators: Khloud Abdo Soliman Elsharawy , Unveiling the role of chromatin remodelers in pediatric tumors of the central nervous system. Funding agency: Instituto de Salud Carlos III Funding: 95000 Reference: CD23/00035 Duration: 01/01/2024 - 31/12/2026
IP: M Mar Mañu Pereira Collaborators: Sara Isabel Reidel , Núria Torquet i Luna, Núria Torquet i Luna, Esther García Pagès, Esther García Pagès, Ángela Menárguez López, Ángela Menárguez López, Clara Durlach, Clara Durlach, Daiana Natali Lopez Funding agency: EUROPEAN COMMISSION Funding: 244375 Reference: IMPACT-AML_M.MAÑU_HE_2022 Duration: 01/04/2023 - 31/03/2028
IP: M Mar Mañu Pereira Collaborators: Sara Isabel Reidel , Anna Collado Gimbert, Ángela Menárguez López, Claire Diot, Amira Idrizovic Funding agency: EUROPEAN COMMISSION Funding: 435937.5 Reference: SYNTHEMA_M.MAÑU_HE_2022 Duration: 01/12/2022 - 30/11/2026
The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.
Vall d'Hebron is one of the centers that coordinate this network, which so far has enabled the detection of high-risk genetic alterations and the provision of personalized treatments that have already achieved remission in cases with very few therapeutic alternatives.
The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.
